A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

Next Previous
Trial Profile

A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Lymphangioleiomyomatosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top